Tickers

1. Composite Trajectory Verdict

For a consumer staples company that has just completed a large acquisition (GOJO) and a venture termination, all three statements carry weight: the income statement reveals margin and earnings pressure, the cash flow statement shows operating cash conversion deteriorating and heavy acquisition financing, and the balance sheet reflects a sharp leverage increase and equity erosion.

Composite Trajectory: Deteriorating

The most recent annual period (FY2026 vs FY2025) shows broad-based deterioration: net sales fell 5.4% to $6.72B, gross margin contracted 290 bps to 42.3%, net earnings dropped 27% to $601M, and diluted EPS fell 26% to $4.81 (10-K 2026-06-30, Consolidated Statements of Operations). Operating cash flow declined 38% to $612M, while total debt (short-term + long-term) surged from $2.488B to $5.067B and stockholders' equity nearly halved from $482M to $252M (10-K 2026-06-30, Consolidated Balance Sheets; Consolidated Statements of Cash Flows). The nine-month quarterly comparison (9M FY2026 vs 9M FY2025) confirms the trend: sales down 7%, gross margin down 200 bps, net earnings down 11%, operating cash flow down 59% (10-Q 2026-03-31, Consolidated Statements of Operations; Consolidated Statements of Cash Flows). The single quarter (Q3 FY2026 vs Q3 FY2025) shows flat sales and EPS but continued margin compression (10-Q 2026-03-31, MD&A). No statement shows an improving trend in the latest comparable periods.

2. Red Flags

• Gross margin compression: FY2026 gross margin 42.3% vs 45.2% in FY2025 (-290 bps); 9M FY2026 42.7% vs 44.7% in 9M FY2025 (-200 bps) (10-K 2026-06-30, Consolidated Statements of Operations; 10-Q 2026-03-31, MD&A).
• Operating cash flow decline: FY2026 net cash from operations $612M vs $981M in FY2025 (-38%); 9M FY2026 $282M vs $687M in 9M FY2025 (-59%), partially driven by a $476M Venture Agreement termination payment (10-K 2026-06-30, Consolidated Statements of Cash Flows; 10-Q 2026-03-31, Consolidated Statements of Cash Flows).
• Leverage surge: Total debt (notes and loans payable + long-term debt) rose from $2.488B (June 2025) to $5.067B (June 2026) and $4.078B (March 2026); commercial paper jumped from $4M to $1.086B (June) / $1.591B (March) (10-K 2026-06-30, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets).
• Equity erosion: Total Clorox stockholders' equity fell from $321M (June 2025) to $90M (June 2026) and -$67M (March 2026) (10-K 2026-06-30, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets).
• Current ratio below 1.0: Current assets $1.824B vs current liabilities $2.773B (0.66x) at June 2026; $2.651B vs $3.155B (0.84x) at March 2026 (10-K 2026-06-30, Consolidated Balance Sheets; 10-Q 2026-03-31, Consolidated Balance Sheets).
• Goodwill and intangibles ballooned: Goodwill up $716M (58%) to $1.945B; Trademarks up $487M (97%) to $989M; Other intangible assets up $542M (847%) to $606M at June 2026 vs June 2025 (10-K 2026-06-30, Consolidated Balance Sheets).
• Recurring "non-recurring" adjustments: Digital transformation costs ($59M in 9M FY2026, $81M in 9M FY2025), acquisition integration costs ($7M in 9M FY2026), and cyberattack insurance recoveries ($70M benefit in 9M FY2025 vs $0 in 9M FY2026) create a widening gap between GAAP and adjusted EBIT (10-Q 2026-03-31, MD&A Non-GAAP Financial Measures).
• Free cash flow below dividends: FY2026 free cash flow (operating - capex) ~$405M vs dividends paid $602M; 9M FY2026 FCF ~$161M vs dividends $452M (10-K 2026-06-30, Consolidated Statements of Cash Flows; 10-Q 2026-03-31, Consolidated Statements of Cash Flows).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

The annual trend shows clear deterioration: FY2026 net sales of $6.72B declined 5.4% from $7.104B in FY2025; gross profit fell 11.5% to $2.844B with margin contracting to 42.3% from 45.2%; earnings before income taxes dropped 26.6% to $791M; net earnings attributable to Clorox fell 27.5% to $587M; diluted EPS declined 26.2% to $4.81 (10-K 2026-06-30, Consolidated Statements of Operations). The nine-month comparison reinforces this: 9M FY2026 net sales $4.772B vs $5.116B (-7%), gross margin 42.7% vs 44.7%, net earnings attributable to Clorox $424M vs $478M (-11%), diluted EPS $3.47 vs $3.84 (-10%) (10-Q 2026-03-31, Consolidated Statements of Operations). The single quarter (Q3) shows flat sales ($1.67B vs $1.668B) and slightly higher diluted EPS ($1.54 vs $1.50) but gross margin still fell 140 bps to 43.2% (10-Q 2026-03-31, MD&A). With three annual periods available, the FY2025→FY2026 step is a sharp reversal from the FY2024→FY2025 improvement.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Reported operating cash flow declined sharply: FY2026 $612M vs FY2025 $981M (-38%); 9M FY2026 $282M vs 9M FY2025 $687M (-59%) (10-K 2026-06-30, Consolidated Statements of Cash Flows; 10-Q 2026-03-31, Consolidated Statements of Cash Flows). The 9M decline was driven primarily by the $476M Venture Agreement termination payment (10-Q 2026-03-31, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow minus capital expenditures) fell from $761M in FY2025 to ~$405M in FY2026 and from $542M in 9M FY2025 to ~$161M in 9M FY2026. Financing cash flows swung to large inflows ($1.668B in FY2026, $857M in 9M FY2026) funded by commercial paper and term debt issuance to finance the GOJO acquisition and Venture payment (10-K 2026-06-30, Consolidated Statements of Cash Flows; 10-Q 2026-03-31, Consolidated Statements of Cash Flows). Dividends paid ($602M FY2026, $452M 9M FY2026) exceeded free cash flow in both periods.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Deteriorating

The balance sheet reflects the impact of the GOJO acquisition and Venture termination financing. Total assets jumped 40% to $7.794B at June 2026 from $5.561B at June 2025, driven by goodwill (+$716M to $1.945B), trademarks (+$487M to $989M), and other intangibles (+$542M to $606M) (10-K 2026-06-30, Consolidated Balance Sheets). Current assets rose 13% to $1.824B, but current liabilities surged 45% to $2.773B, pushing the current ratio to 0.66x from 0.84x (10-K 2026-06-30, Consolidated Balance Sheets). Long-term debt increased 60% to $3.981B; total liabilities rose 49% to $7.542B. Total Clorox stockholders' equity fell 72% to $90M (including noncontrolling interests, total equity $252M vs $482M) (10-K 2026-06-30, Consolidated Balance Sheets). At March 2026, cash was $1.187B (vs $167M at June 2025) but current liabilities were $3.155B with $1.591B in commercial paper, and total equity was just $92M (10-Q 2026-03-31, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly data for Q1 and Q2 of FY2025 (to enable four-quarter YoY trends for FY2026 quarters)
• Annual data for FY2023 and earlier (to assess longer-term earnings and cash flow trends beyond three years)
• Segment-level GAAP operating margins (only non-GAAP segment adjusted EBIT is provided in MD&A)
• Full-year organic sales growth breakdown (only 9-month and Q3 organic sales reconciliation provided)
• Detailed debt maturity schedule beyond the revolving credit agreements described in the 10-Q
• Post-acquisition GOJO integration costs and synergy realization timeline (only acquisition/integration costs of $7M in 9M FY2026 disclosed)